Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Express Scripts
Harvard Business School
Argus Health
Citi

Generated: August 17, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,784,408

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,784,408
Title:LED treatment of dermatologic toxicities associated with vascular endothelial growth factor inhibitors
Abstract: The present invention relates generally to methods of preventing or treating toxicities of the skin, hair, and/or nails, which are associated with administration of one or more vascular endothelial growth factor receptor inhibitors, with light-emitting diode photomodulation treatment, either alone or in combination with other agents.
Inventor(s): DeLand; M. Maitland (Lafayette, LA), Weiss; Robert A. (Baltimore, MD)
Assignee:
Application Number:13/020,313
Patent Claims:1. A method of treating or preventing skin toxicity associated with administration of a vascular endothelial growth factor (VEGF) inhibitor in a subject in need thereof, said method, comprising directing light onto a target area on said subject, wherein said subject is administered a VEGF inhibitor therapy, said light being emitted from one or more light emitting diode (LED) sources producing at least one range of wavelengths of light, said light comprising about 90% of a wavelength of about 590 nm and about 10% of a wavelength of about 870 nm, said light further comprising pulses of light that are 250 ms in duration that are separated by 100 ms, and are repeated 100 times, wherein skin toxicity is in the dermis and is treated or prevented in the subject.

2. The method according to claim 1, wherein said toxicity is associated with inflammation of said skin.

3. The method according to claim 1, wherein said VEGF inhibitor is selected from the group consisting of bevacizumab, sunitinib and sorafenib.

4. The method according to claim 1, wherein said skin toxicity is in the epidermis.

5. The method according to claim 1, wherein said skin toxicity is in the subcutaneous layer of the skin.

6. The method according to claim 1, wherein said skin toxicity is an acneiform rash that is not caused by bacteria.

7. The method according to claim 1, wherein said skin toxicity is a papulopustular rash.

8. The method according to claim 1, wherein said skin toxicity is pruritis.

9. The method according to claim 1, wherein said skin toxicity comprises palmar-plantar erythrodysesthesia.

10. The method according to claim 1, wherein said skin toxicity comprises one or more symptoms of palmar-plantar erythrodysesthesia.

11. The method according to claim 1, wherein said skin toxicity is classified as an NCI-CTC grade 1, grade 2, grade 3, or grade 4 rash.

12. The method according to claim 11, wherein said skin toxicity is classified as an NCI-CTC grade 2.

13. The method according to claim 1, further comprising administration of one or more additional agents.

14. The method according to claim 13, wherein the agent is lotion containing copper.

15. The method according to claim 1, wherein the target area is selected from the group consisting of the face, neck, back, scalp, hands, and feet.

16. The method according to claim 1, wherein the LED source emits light at a wavelength from 500 nm to 700 nm.

17. The method according to claim 1, wherein the LED source emits light at a wavelength of 590 nm.

18. The method according to claim 1, wherein the light from the LED source is administered once daily.

19. The method according to claim 1, wherein the light from the LED source is administered beginning prior to the administration of VEGF inhibitor therapy.

20. The method according to claim 1, wherein the light from the LED source is administered concurrent with the administration of VEGF inhibitor therapy.

21. The method according to claim 1, wherein the light from the LED source is administered following an initial dose of VEGF inhibitor therapy.

22. The method according to claim 1, wherein the LED delivers a total energy fluence of 0.15 J/cm.sup.2.

Details for Patent 8,784,408

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial 2030-02-05 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial 2030-02-05 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Accenture
Argus Health
Federal Trade Commission
Cipla
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.